Verastem, Inc. (VSTM)Healthcare | Biotechnology | Needham, United States | NasdaqCM
7.45 USD
-0.80
(-9.697%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 7.53 +0.08 (1.043%) ⇧ (Oct. 13, 2026, 7:54 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 8:06 a.m. EDT
Verastem presents a classic biotech dilemma: a strong analyst consensus and recent revenue growth masking severe fundamental deterioration. While the company boasts a 17.7% revenue increase and robust gross margins, the bottom line is bleeding heavily, with operating cash flow and free cash flow both deeply negative. The balance sheet is precarious, carrying debt that exceeds equity, and the stock has suffered a brutal 52.7% decline over the last nine years, despite a massive 187% rebound in the most recent fiscal year. This volatility suggests the market is currently pricing in a binary event—either a clinical success that validates the recovery or a failure that triggers another collapse. With no dividend to provide income and a high short ratio indicating skepticism among leveraged investors, the risk-reward profile is skewed against the buyer until a definitive catalyst resolves the uncertainty. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.092486 |
| MSTL | 0.137873 |
| AutoETS | 0.141574 |
| AutoARIMA | 0.193996 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 10.34 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.387 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 168.707 |
| Revenue per Share | 0.985 |
| Market Cap | 674,697,600 |
| Forward P/E | -9.93 |
| Beta | 0.39 |
| Profit Margins | -231.59% |
| Website | https://www.verastem.com |
As of Oct. 10, 2026, 8:06 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a decisive breakout. Call open interest is heavily concentrated at the $9.00 strike, creating a wall of resistance that suggests traders expect the price to struggle to breach this level in the near term. Conversely, put open interest is stacked significantly lower at the $5.00 and $6.00 strikes, indicating a floor where sellers believe the asset will find support. The lack of deep out-of-the-money call volume and the dominance of OTM puts suggest a 'mean reversion' or consolidation strategy is favored over aggressive directional bets.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.12234044 |
| Address1 | 117 Kendrick Street |
| Address2 | Suite 500 |
| All Time High | 225.84 |
| All Time Low | 2.1 |
| Ask | 9.62 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.1 - Strong Buy |
| Average Daily Volume10 Day | 2,834,040 |
| Average Daily Volume3 Month | 2,259,230 |
| Average Volume | 2,259,230 |
| Average Volume10Days | 2,834,040 |
| Beta | 0.387 |
| Bid | 5.84 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.552 |
| City | Needham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.45 |
| Current Ratio | 2.255 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 8.2 |
| Day Low | 7.45 |
| Debt To Equity | 168.707 |
| Display Name | Verastem |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,048,200 |
| Earnings Call Timestamp Start | 1,786,048,200 |
| Earnings Timestamp | 1,786,046,400 |
| Earnings Timestamp End | 1,793,736,000 |
| Earnings Timestamp Start | 1,793,736,000 |
| Ebitda | -158,647,008 |
| Ebitda Margins | -1.8125701 |
| Enterprise To Ebitda | -3.925 |
| Enterprise To Revenue | 7.114 |
| Enterprise Value | 622,674,624 |
| Eps Current Year | -1.8 |
| Eps Forward | -0.75 |
| Eps Trailing Twelve Months | -2.45 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 7.4188 |
| Fifty Day Average Change | 0.031199932 |
| Fifty Day Average Change Percent | 0.0042055226 |
| Fifty Two Week Change Percent | -12.234044 |
| Fifty Two Week High | 10.82 |
| Fifty Two Week High Change | -3.37 |
| Fifty Two Week High Change Percent | -0.31146026 |
| Fifty Two Week Low | 3.43 |
| Fifty Two Week Low Change | 4.0199995 |
| Fifty Two Week Low Change Percent | 1.1720115 |
| Fifty Two Week Range | 3.43 - 10.82 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,327,674,600,000 |
| Float Shares | 70,500,922 |
| Forward Eps | -0.75 |
| Forward P E | -9.933333 |
| Free Cashflow | -103,429,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 102 |
| Fullday Change | -0.72230005 |
| Fullday Change Percent | -8.755152 |
| Fullday Price | 7.45 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.87644994 |
| Gross Profits | 76,712,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01091 |
| Held Percent Institutions | 1.10429 |
| Implied Shares Outstanding | 90,563,441 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,685,577,600 |
| Last Split Factor | 1:12 |
| Long Business Summary | Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS, which in Phase 1/2 trial entitled RAMP 203; VS-7375, and VS-7375-101 is a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers; and AVMAPKI, FAKZYNJA, CO-PACK, is an avutometinib capsules, and defactinib tablets. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts. |
| Long Name | Verastem, Inc. |
| Market | us_market |
| Market Cap | 674,697,600 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_115881768 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -202,698,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 740,356,130 |
| Number Of Analyst Opinions | 9 |
| Open | 8.2 |
| Operating Cashflow | -162,195,008 |
| Operating Margins | -0.81615996 |
| Overall Risk | 7 |
| Phone | 781 292 4200 |
| Post Market Change | 0.07770014 |
| Post Market Change Percent | 1.0429549 |
| Post Market Price | 7.5277 |
| Post Market Time | 1,791,935,665 |
| Previous Close | 8.25 |
| Price Eps Current Year | -4.138889 |
| Price Hint | 2 |
| Price To Book | 13.496377 |
| Price To Sales Trailing12 Months | 7.708539 |
| Profit Margins | -2.31586 |
| Quick Ratio | 2.119 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.1 |
| Region | US |
| Regular Market Change | -0.8 |
| Regular Market Change Percent | -9.69697 |
| Regular Market Day High | 8.2 |
| Regular Market Day Low | 7.45 |
| Regular Market Day Range | 7.45 - 8.2 |
| Regular Market Open | 8.2 |
| Regular Market Previous Close | 8.25 |
| Regular Market Price | 7.45 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 3,394,496 |
| Return On Assets | -0.49592 |
| Return On Equity | -4.7116103 |
| Revenue Growth | 17.754 |
| Revenue Per Share | 0.985 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 90,563,441 |
| Shares Percent Shares Out | 0.16520001 |
| Shares Short | 14,964,825 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 18,298,315 |
| Short Name | Verastem, Inc. |
| Short Percent Of Float | 0.16620001 |
| Short Ratio | 6.19 |
| Source Interval | 15 |
| State | MA |
| Symbol | VSTM |
| Target High Price | 19.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 15.0 |
| Target Median Price | 14.0 |
| Total Cash | 136,352,992 |
| Total Cash Per Share | 1.506 |
| Total Debt | 84,330,000 |
| Total Revenue | 87,526,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.45 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 6.0426 |
| Two Hundred Day Average Change | 1.4073997 |
| Two Hundred Day Average Change Percent | 0.23291293 |
| Type Disp | Equity |
| Volume | 3,394,496 |
| Website | https://www.verastem.com |
| Zip | 2,494 |